Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios

被引:7
|
作者
A'Hern, R. P.
机构
关键词
Cancer biology; Cox regression; proportional hazards; restricted mean survival time analysis; survival analysis; RANDOMIZED CLINICAL-TRIALS; METASTATIC BREAST-CANCER; GROWTH-RATES; COLON-CANCER; PROGRESSION; DATABASE; THERAPY;
D O I
10.1016/j.clon.2018.04.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hazard ratios are commonly used when comparing survival between two groups and make the assumption that the relative event rates do not change markedly during follow-up, i.e. that event rates are proportional. However, there is currently debate about the use of the proportional hazards assumption to summarise the treatment effect in survival analysis compared with restricted mean survival time (RMST) analysis, particularly in cancer trials. In many situations it is unrealistic to assume that relative event rates in two groups will be proportional throughout follow-up and, hence, RMST analysis, which does not make this assumption, may be preferable. Several benefits of the latter approach have been identified but the biological perspective is not often discussed. Biological features such as the patterns of tumour growth and response can also contribute to assessing the relative merit of these two methods; such biological considerations are the subject of this paper. The observation that the most commonly observed approximation to the underlying distribution of time to event data, the lognormal distribution, does not reliably show proportional hazards in the comparison of two groups, lends weight to a statistical approach that is not based on proportional hazards. The proportional hazards assumption should be viewed more critically when estimating treatment effects. An optimum approach may be to include both proportional hazards analysis and RMST analysis when comparing time to event endpoints. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E75 / E80
页数:6
相关论文
共 50 条
  • [21] Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point
    Huang, Bo
    Kuan, Pei-Fen
    [J]. PHARMACEUTICAL STATISTICS, 2018, 17 (03) : 202 - 213
  • [22] Restricted mean survival time (RMST): A new tool for time to event analysis in young breast cancer patients (YBCP)
    Sanchez, J. C.
    Mendez Garcia, M.
    Nunez Garcia, B.
    Blanco Clemente, M.
    Mucientes, J.
    Lopez Valcarcel, M.
    Aguado, R.
    Royuela, A.
    Provencio Pulla, M.
    Sanchez de Ibarguen, B. Cantos
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S84 - S85
  • [23] Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies
    Rivano, Melania
    Cancanelli, Luca
    Di Spazio, Lorenzo
    Chiumente, Marco
    Mengato, Daniele
    Messori, Andrea
    [J]. IMMUNOTHERAPY, 2021, 13 (02) : 95 - 101
  • [24] ANALYSIS OF SURVIVAL IN CANCER CLINICAL-TRIALS
    SHIMM, D
    LOGUE, G
    [J]. ANNALS OF INTERNAL MEDICINE, 1983, 98 (05) : 665 - 666
  • [25] Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
    Wang, Zi-Xian
    Wu, Hao-Xiang
    Xie, Li
    Wang, Ying-Nan
    Yang, Lu-Ping
    He, Ming-Ming
    Luo, Hui-Yan
    Ding, Pei-Rong
    Xie, Dan
    Chen, Gong
    Li, Yu-Hong
    Wang, Feng
    Xu, Rui-Hua
    [J]. JAMA NETWORK OPEN, 2019, 2 (05)
  • [26] Evaluation of Overall Survival by Restricted Mean Survival Time of Advanced Biliary Tract Cancer treated with Immunotherapy: A Systematic Review and Meta-Analysis
    Mauro, Ezequiel
    Sanduzzi-Zamparelli, Marco
    Sauri, Tamara
    Soler, Alexandre
    Iserte, Gemma
    Fortuny, Marta
    Forner, Alejandro
    [J]. CANCERS, 2024, 16 (11)
  • [27] Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails
    Ueno, Kentaro
    Morita, Satoshi
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 467 - 471
  • [28] Analysis of restricted mean survival time for length-biased data
    Lee, Chi Hyun
    Ning, Jing
    Shen, Yu
    [J]. BIOMETRICS, 2018, 74 (02) : 575 - 583
  • [29] Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails
    Kentaro Ueno
    Satoshi Morita
    [J]. Therapeutic Innovation & Regulatory Science, 2023, 57 : 467 - 471
  • [30] A Model-Independent Method to Determine Restricted Mean Survival Time in the Analysis of Survival Curves
    Andrea Messori
    Vera Damuzzo
    Laura Agnoletto
    Luca Leonardi
    Marco Chiumente
    Daniele Mengato
    [J]. SN Comprehensive Clinical Medicine, 2020, 2 (1) : 66 - 68